Yiping Yang, MD, PhD
Leadership Title: Director, Division of Hematology Jeg Coughlin Chair in Cancer Research
Academic Title: Professor in the College of Medicine
About Me
More info forI am a nationally recognized expert in cancer immunology and immunotherapy who serves as the director of the Division of Hematology at The Ohio State University. I specialize in the treatment of lymphoma, leukemia and virus-associated malignancies.
My research interests focus on tumor immunology and viral immunity, with the ultimate goal of developing effective immunotherapy approaches for treating cancer. Current projects include investigating novel NK and T cell-mediated strategies for cancer immunotherapy with stem cell transplant, understanding mechanisms for the generation of long-lived tumor-specific memory T cells, and numerous studies focused on enhancing scientific understanding of the elements of the tumor microenvironment in cancer development and progression.
Additionally, I will be an important collaborator in the new Pelotonia Institute for Immuno-Oncology (PIIO), a comprehensive bench-to-bedside research initiative at the OSUCCC – James launched in July 2019 under the leadership of Zihai Li, PhD. The PIIO is focused on harnessing the body’s immune system to fight cancer at all levels – from prevention to treatment and survivorship.
My work has generated more than 100 peer-reviewed manuscripts published in leading scientific journals and has culminated in multiple current principal investigator R01 grants from the National Institutes of Health. I am an elected member of the American Society for Clinical Investigation and a fellow of the Alliance for Cancer Gene Therapy.
I have also assumed numerous national leadership roles related to research and education, including serving on the National Institutes of Health’s Immune Mechanisms of Viral Control Program committee, as well as the American Society of Gene and Cell Therapy’s Immunology of Gene & Cell Therapy and Cancer Gene & Cell Therapy committees. A recognized leader in the field of immune mechanisms, he is a past associate editor of the Journal of Clinical Investigation and current associate editor of the Journal of Clinical Investigation Insight.
Clinical Expertise
More info for- Lymphomas
- Immunotherapy
- Leukemia
Education & Training
More info forDoctorate - PhD
- University of Michigan
Ann Arbor, MI
USA
Doctorate - MD
- Zheijiang University School of Medicine
Hangzhou, Zhejiang
China
- University of Michigan
Academic Office & Contact Information
More info forAcademic Office:
320 W 10th Ave
Columbus, Ohio 43210-1280Email:
yang.5468@osu.eduPublications
More info forMarch 23, 2024Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.
Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz R, Miao J, Song C, Wu D, Chan WK, Bezerra ED, Epperla N, Voorhees TJ, Brammer JE, Kittai AS, Bond DA, Sawalha Y, Sigmund AM, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks KJ, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski SM, Li Z, Huang X, Yang Y
Blood Adv
January 1, 2024Stem-like CD8+ T cells in cancer.
Steiner C, Denlinger N, Huang X, Yang Y
Front Immunol
September 22, 2023A novel CAR-T cell product targeting CD74 is an effective therapeutic approach in preclinical mantle cell lymphoma models.
Chan WK, Williams J, Sorathia K, Pray B, Abusaleh K, Bian Z, Sharma A, Hout I, Nishat S, Hanel W, Sloan SL, Yasin A, Denlinger N, Zhang X, Muthusamy N, Vasu S, de Lima M, Yang Y, Baiocchi R, Alinari L
Exp Hematol Oncol
May 26, 2023A Pilot Cross-Sectional Study of Immunological and Microbiome Profiling Reveals Distinct Inflammatory Profiles for Smokers, Electronic Cigarette Users, and Never-Smokers.
Shields PG, Ying KL, Brasky TM, Freudenheim JL, Li Z, McElroy JP, Reisinger SA, Song MA, Weng DY, Wewers MD, Whiteman NB, Yang Y, Mathé EA
Microorganisms
January 6, 2023Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.
Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R
Nat Commun
September 1, 2022Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity.
Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, Velegraki M, Giuliani GD, Das K, Okimoto T, Kwon H, Chakravarthy KB, Bolyard C, Wang Y, He K, Gatti-Mays M, Das J, Yang Y, Gewirth DT, Ma Q, Carbone D, Li Z
J Immunother Cancer
April 5, 2022Redefining CD56 as a biomarker and therapeutic target in Multiple Myeloma.
Cottini F, Rodriguez J, Hughes T, Sharma N, Guo L, Lozanski G, Liu B, Cocucci E, Yang Y, Benson D
Mol Cancer Res
January 8, 2022Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH
Clin Lung Cancer
July 7, 2021Functional expression of aryl hydrocarbon receptor as a potential novel therapeutic target in human multiple myeloma.
Hughes T, Cottini F, Catton E, Ciarlariello D, Chen L, Yang Y, Liu B, Mundy-Bosse BL, Benson DM
Leuk Lymphoma
March 22, 2021Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
Petty AJ, Dai R, Lapalombella R, Baiocchi RA, Benson DM, Li Z, Huang X, Yang Y
JCI Insight
February 2, 2021Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia.
Ge Z, Song C, Ding Y, Tan BH, Desai D, Sharma A, Gowda R, Yue F, Huang S, Spiegelman V, Payne JL, Reeves ME, Iyer S, Dhanyamraju PK, Imamura Y, Bogush D, Bamme Y, Yang Y, Soliman M, Kane S, Dovat E, Schramm J, Hu T, McGrath M, Chroneos ZC, Payne KJ, Gowda C, Dovat S
Leukemia
May 12, 2020IKAROS and CK2 regulate expression of BCL-XL and chemosensitivity inhigh-risk B-cell acute lymphoblastic leukemia.
Song C, Ge Z, Ding Y, Tan BH, Desai D, Gowda K, Amin SG, Gowda R, Robertson G, Yue F, Huang S, Spiegelman V, Payne J, Reeves M, Gurel Z, Iyer S, Dhanyamraju PK, Xiang M, Kawasawa YI, Cury NM, Yunes JA, McGrath M, Schramm J, Su RJ, Yang Y, Zhao Z, Lyu X, Müschen M, Payne KJ, Gowda C, Dovat S
Blood